Pervaiz Malik
Interventional Cardiology · Montgomery, ALNPI 1275530636
Payments from drug & device makers
Across 237 payments — averaging $18.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Novartis$429
- Pfizer$391
- Biotronik Inc.$304
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$274
- Merck$203
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,450100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 67 | $1,017 |
| Novartis | 32 | $429 |
| Pfizer | 20 | $391 |
| Biotronik Inc. | 3 | $304 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $274 |
| Merck | 11 | $203 |
| Medtronic | 3 | $164 |
| E.r. Squibb & Sons, L.L.C. | 10 | $150 |
| Lantheus Medical Imaging, Inc. | 2 | $121 |
| Bayer | 6 | $120 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $104 |
| Boehringer Ingelheim | 7 | $104 |
| Philips North America LLC | 5 | $102 |
| W. L. Gore & Associates, Inc. | 1 | $101 |
| Abbott | 5 | $93 |
| Actelion Pharmaceuticals US, Inc. | 5 | $85 |
| Akcea Therapeutics, Inc. | 4 | $79 |
| AstraZeneca | 5 | $73 |
| Lexicon Pharmaceuticals, Inc. | 4 | $69 |
| Amgen | 4 | $58 |
| GE HealthCare | 1 | $58 |
| Novo Nordisk | 2 | $42 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Baxter Healthcare | 2 | $39 |
| Sanofi-aventis U.S. LLC | 2 | $38 |
| United Therapeutics Corporation | 2 | $28 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $17 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $17 |
| GSK | 1 | $17 |
| Boston Scientific | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Atricure, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Orsiro Mission$135
- COREVALVE EVOLUT R$111
- XARELTO$107
- INVOKANA$104
- CARDIOFORM Septal Occluder$101
- Definity$101
How this compares
$4,464 in reported general payments places this provider in the 30th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 501 | $456,048 |
| UptraviSelexipag | 12 | $279,740 |
| EntrestoSacubitril/Valsartan | 136 | $189,978 |
| AdempasRiociguat | 12 | $169,052 |
| XareltoRivaroxaban | 176 | $155,255 |
| OpsumitMacitentan | 12 | $148,312 |
| Bosentan | 12 | $70,712 |
| FarxigaDapagliflozin Propanediol | 41 | $35,221 |
| Praluent PenAlirocumab | 18 | $20,149 |
| Repatha SureclickEvolocumab | 21 | $13,368 |
| BrilintaTicagrelor | 18 | $11,807 |
| Prasugrel Hcl | 123 | $8,764 |
| Metoprolol Succinate | 454 | $8,517 |
| Atorvastatin Calcium | 365 | $6,528 |
| Carvedilol | 526 | $4,816 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit, Bosentan | $85 | $498,76336 claims |
| PfizerEliquis | $391 | $456,048501 claims |
| NovartisEntresto | $429 | $189,978136 claims |
| BayerAdempas | $120 | $169,05212 claims |
| Johnson & JohnsonXarelto | $1,017 | $155,255176 claims |
| AstraZenecaFarxiga, Brilinta | $73 | $47,02859 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Montgomery
- Thomas WoolMontgomery$45K
- Sergio Perez BeracasaMontgomery$25K
- John KolawoleMontgomery$23K
- Taimoor HashimMontgomery$12K
- Ashwini SharmaMontgomery$8K
- John LedouxMobile$2.3M
- Alejandro VasquezHuntsville$1.2M
- Michael ButlerHuntsville$919K
- Robert FosterBirmingham$553K
- Chad AlfordMobile$461K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.